Immuno-Oncology | Specialty

Dr. Grivas on Mechanisms of Immune Response in Bladder Cancer

December 18th 2018

Petros Grivas, MD, PhD, director, University of Washington Medicine’s Genitourinary Cancers Program, associate professor, Oncology, University of Washington, Seattle Cancer Care Alliance, discusses mechanisms of immune response in bladder cancer.

Expert Highlights Utility of PD-L1 to Select Immunotherapy in NSCLC

December 14th 2018

Amishi Desai, MD, highlights new and emerging data regarding the use of immunotherapy in patients with non–small lung cancer.

Powles Navigates Rapidly Evolving Frontline Paradigm in Urothelial Carcinoma

December 13th 2018

Thomas Powles MBBS, MRCP, MD, discusses the changes to the frontline landscape of bladder cancer and where research should focus moving forward.

Real-World Findings Support Nivolumab Use in HNSCC

December 12th 2018

Nivolumab demonstrated durable response and overall survival rates in a real-world analysis of patients with platinum-refractory, recurrent/metastatic head and neck squamous cell carcinoma.

Dr. Choueiri on Next Steps for Treatment in RCC

December 12th 2018

Toni Choueiri, MD, director, Lank Center for Genitourinary Oncology, director, Kidney Cancer Center, Jerome and Nancy Kohlberg Associate Professor of Medicine, Harvard Medical School, Dana-Farber Cancer Institute, discusses next steps for treatment in renal cell carcinoma.

PACIFIC Trial Changes Standard of Care in Stage III NSCLC

December 12th 2018

Adham Jurdi, MD, discusses how the updated data from the PACIFIC trial have changed the standard of care for patients with stage III non–small cell lung cancer.

Immunotherapy Changes Early-Stage Urothelial Carcinoma Paradigm

December 11th 2018

Newer immunotherapy agents are changing traditional strategies for care, resulting in higher levels of collaboration.

Durvalumab Falls Short in Head and Neck Cancer

December 8th 2018

Durvalumab alone and in combination with tremelimumab did not improve overall survival versus standard-of-care chemotherapy in patients with recurrent or metastatic head and neck squamous cell carcinoma who progressed after platinum-based chemotherapy.

Dr. Somer on Immunotherapy Combinations in mRCC

December 8th 2018

Bradley G. Somer, MD, associate professor of hematology/oncology, head of strategic expansion/development, University of Tennessee West Cancer Center, discusses the potential for immunotherapy combinations in metastatic renal cell carcinoma.

Neoadjuvant Immunotherapy Has Potential in Stage IIIa NSCLC

December 7th 2018

Nisha A. Mohindra, MD, discusses the current treatment landscape, challenges faced in this patient population, and what she believes will be a focus for further research over the next decade.

FDA Approves Frontline Atezolizumab Regimen for NSCLC

December 7th 2018

The FDA has approved atezolizumab for use in combination with bevacizumab, carboplatin, and paclitaxel for the first-line treatment of patients with metastatic nonsquamous non-small cell lung cancer.

Dr. Amin on CheckMate-214 Trial in RCC

December 6th 2018

Asim Amin, MD, PhD, director of immunotherapy, Levine Cancer Institute, discusses the rationale for the pivotal CheckMate-214 trial in advanced renal cell carcinoma.

Investigators Seek Expanded Use of Checkpoint Inhibitors in RCC

December 5th 2018

In contrast to the wide array of available therapies in the metastatic setting of renal cell carcinoma, in patients with localized disease, the results of trials investigating adjuvant systemic therapy after nephrectomy have so far been underwhelming.

FDA Grants Atezolizumab Regimen Priority Review for Frontline SCLC

December 5th 2018

The FDA has granted a priority review designation to a supplemental biologics license application for atezolizumab for use in combination with carboplatin and etoposide for the frontline treatment of patients with extensive-stage small cell lung cancer.

Dr. Choueiri on Frontline Trials of Immunotherapy in RCC

December 4th 2018

Toni Choueiri, MD, director, Lank Center for Genitourinary Oncology, director, Kidney Cancer Center, Jerome and Nancy Kohlberg Associate Professor of Medicine, Harvard Medical School, Dana-Farber Cancer Institute, discusses frontline trials of immunotherapy in renal cell carcinoma.

Dr. Burtness on the Benefit of Pembrolizumab in Head and Neck Cancer

December 1st 2018

Barbara Burtness, MD, professor of medicine, Yale Cancer Center, discusses the benefit of pembrolizumab (Keytruda) as a treatment for patients with recurrent metastatic head and neck squamous cell carcinoma.

Avelumab Continues to Show Value in JAVELIN Merkel 200 Analyses

December 1st 2018

In an analysis of patient-reported outcomes of the JAVELIN Merkel 200 trial of avelumab (Bavencio), investigators found that there was a similarity in proportion of responders with metastatic Merkel cell carcinoma based on clinical and patient-reported outcome endpoints.

Brahmer Shares Next Steps for Immunotherapy in Metastatic NSCLC

December 1st 2018

Julie R. Brahmer, MD, discusses updates on the use of immunotherapy in patients with metastatic non–small cell lung cancer.

Cemiplimab Explored in Advanced Basal Cell Carcinoma

November 30th 2018

An ongoing phase II study evaluating the PD-1 inhibitor cemiplimab in patients with basal cell carcinoma may prove efficacious based on its activity in other advanced malignancies.

Immunotherapy May Have Place Among TKI Boom in EGFR+ NSCLC

November 30th 2018

Within the last decade, 4 tyrosine kinase inhibitors have been approved for the frontline treatment of patients with EGFR-positive non–small cell lung cancer.

NEXT PAGE
PREVIOUS PAGE